July 28 (Reuters) – Johnson & Johnson (JNJ.N) contractor Emergent BioSolutions Inc (EBS.N) plans to resume COVID-19 vaccine production at its Baltimore plant after getting approval from the U.S. Food and Drug Administration (FDA), the Wall Street Journal reported late on Wednesday, citing a statement from the company and a FDA letter.
Production of J&J’s COVID-19 vaccine at the Baltimore site was halted by U.S. authorities in April following a discovery that ingredients from AstraZeneca’s (AZN.L) COVID-19 vaccine, also being produced at the plant at that time, contaminated a batch of J&J’s vaccines.
J&J, Emergent and the FDA did not immediately respond to Reuters requests for comment.
Reporting by Aishwarya Nair in Bengaluru; Editing by Subhranshu Sahu
Our Standards: The Thomson Reuters Trust Principles.